Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion

被引:282
作者
Platet, N
Cathiard, AM
Gleizes, M
Garcia, M
机构
[1] INSERM, Unite 540, F-34090 Montpellier, France
[2] Univ Montpellier I, F-34090 Montpellier, France
关键词
estrogen receptor; invasion; breast cancer; therapy;
D O I
10.1016/j.critrevonc.2004.02.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Estrogens play an important role in regulating the growth and differentiation of normal, premalignant and malignant cell types, especially breast epithelial cells, through interaction with two nuclear estrogen receptors (ERalpha and ERbeta). In this review, we present a brief overview of the actions of estrogens in the different steps of breast carcinogenesis, including cancer progression to metastasis, and of their clinical consequences in the prevention, prognosis and treatment of the disease. The requirement of estrogen receptors, mainly of the alpha subtype, in normal mammary gland differentiation and growth has been evidenced by estrogen receptor deficiency in animals. The promotion of breast cancer carcinogenesis by prolonged exposure to estrogens is well-documented and this has logically led to the use of anti-estrogens as potentially chemopreventive agents. In breast cancer progression, however, the exact roles of estrogen receptors have been less well established but they may possibly be dual. Estrogens are mitogenic in ER-positive cells and anti-estrogens are an efficient adjuvant therapy for these tumors. On the other hand, the fact that estrogens and their receptors protect against cancer cell invasiveness through distinct mechanisms in experimental models may explain why the presence of ER is associated with well-differentiated and less invasive tumors. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:55 / 67
页数:13
相关论文
共 123 条
[1]  
ADAMS J, 1981, CANCER RES, V41, P4720
[2]   17-BETA-ESTRADIOL REGULATES AND V-HA-RAS TRANSFECTION CONSTITUTIVELY ENHANCES MCF7 BREAST-CANCER CELL-INTERACTIONS WITH BASEMENT-MEMBRANE [J].
ALBINI, A ;
GRAF, J ;
KITTEN, GT ;
KLEINMAN, HK ;
MARTIN, GR ;
VEILLETTE, A ;
LIPPMAN, ME .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (21) :8182-8186
[3]   Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases [J].
Bardou, VJ ;
Arpino, G ;
Elledge, RM ;
Osborne, CK ;
Clark, GM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :1973-1979
[4]  
Beatson GT., 1896, LANCET, V148, P104, DOI DOI 10.1016/S0140-6736(01)72307-0
[5]  
Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
[6]  
Beral Valerie, 2003, Lancet, V362, P419, DOI 10.1016/S0140-6736(03)14065-2
[7]   ROLE OF THE 2 ACTIVATING DOMAINS OF THE ESTROGEN-RECEPTOR IN THE CELL-TYPE AND PROMOTER-CONTEXT DEPENDENT AGONISTIC ACTIVITY OF THE ANTIESTROGEN 4-HYDROXYTAMOXIFEN [J].
BERRY, M ;
METZGER, D ;
CHAMBON, P .
EMBO JOURNAL, 1990, 9 (09) :2811-2818
[8]  
Blaschuk O W, 1994, Can J Oncol, V4, P291
[9]  
BRACKE ME, 1994, CANCER RES, V54, P4607
[10]   Molecular basis of agonism and antagonism in the oestrogen receptor [J].
Brzozowski, AM ;
Pike, ACW ;
Dauter, Z ;
Hubbard, RE ;
Bonn, T ;
Engstrom, O ;
Ohman, L ;
Greene, GL ;
Gustafsson, JA ;
Carlquist, M .
NATURE, 1997, 389 (6652) :753-758